H. De Jong

Clinical use of the mRNA urinary biomarker SelectMDx test for prostate cancer

J. Schalken, W. Melchers, P. Mulders, 2022, Prostate Cancer and Prostatic Diseases.

Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer

T. D. de Reijke, J. Schalken, H. Vergunst, 2015, Clinical Cancer Research.

Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.

T. D. de Reijke, J. Schalken, H. Vergunst, 2014, European urology.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Geert Trooskens, Wim Van Criekinge, Theo M de Reijke, 2016, European urology.

KLK3, PCA3, and TMPRSS2‐ERG expression in the peripheral blood mononuclear cell fraction from castration‐resistant prostate cancer patients and response to docetaxel treatment

J. Schalken, P. Mulders, I. V. van Oort, 2014, The Prostate.

Commercialized Blood-, Urinary- and Tissue-Based Biomarker Tests for Prostate Cancer Diagnosis and Prognosis

J. Schalken, W. Melchers, P. Mulders, 2020, Cancers.

Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-naïve men

E. Crawford, C. Hulsbergen-van de Kaa, J. Barentsz, 2021, Prostate Cancer and Prostatic Diseases.

KLK3, PCA3, and TMPRSS2‐ERG expression in the peripheral blood mononuclear cell fraction from castration‐resistant prostate cancer patients and response to docetaxel treatment

J. Schalken, P. Mulders, I. V. van Oort, 2014, The Prostate.